$198 Million is the total value of EcoR1 Capital, LLC's 22 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KITE | New | KITE PHARMA INC | $25,283,000 | – | 438,400 | +100.0% | 12.80% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $21,523,000 | – | 384,348 | +100.0% | 10.89% | – |
| RCPT | New | RECEPTOS INC | $17,862,000 | – | 145,801 | +100.0% | 9.04% | – |
| New | ARRAY BIOPHARMA INCnote 3.00% 6/0 | $16,250,000 | – | 17,500,000 | +100.0% | 8.22% | – | |
| MGNX | New | MACROGENICS INC | $15,909,000 | – | 453,626 | +100.0% | 8.05% | – |
| IRWD | New | IRONWOOD PHARMACEUTICALS INC | $13,788,000 | – | 900,000 | +100.0% | 6.98% | – |
| FGEN | New | FIBROGEN INC | $10,936,000 | – | 400,000 | +100.0% | 5.53% | – |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $10,133,000 | – | 385,124 | +100.0% | 5.13% | – |
| KIN | New | KINDRED BIOSCIENCES INC | $9,644,000 | – | 1,294,431 | +100.0% | 4.88% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $9,069,000 | – | 491,044 | +100.0% | 4.59% | – |
| KERX | New | KERYX BIOPHARMACEUTICALS INCcall | $8,334,000 | – | 589,000 | +100.0% | 4.22% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $7,937,000 | – | 1,009,752 | +100.0% | 4.02% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $6,479,000 | – | 328,070 | +100.0% | 3.28% | – |
| GNVC | New | GENVEC INC | $4,132,000 | – | 1,986,413 | +100.0% | 2.09% | – |
| CALA | New | CALITHERA BIOSCIENCES INC | $4,074,000 | – | 201,700 | +100.0% | 2.06% | – |
| VTAE | New | VITAE PHARMACEUTICALS INC | $3,444,000 | – | 207,000 | +100.0% | 1.74% | – |
| OMED | New | ONCOMED PHARMACEUTICALS INC | $3,417,000 | – | 157,038 | +100.0% | 1.73% | – |
| PRTK | New | PARATEK PHARMACEUTICALS INC | $3,044,000 | – | 78,958 | +100.0% | 1.54% | – |
| FWP | New | FORWARD PHARMA A/Ssponsored adr | $2,083,000 | – | 100,000 | +100.0% | 1.05% | – |
| TRGT | New | TARGACEPT INC | $1,630,000 | – | 619,699 | +100.0% | 0.82% | – |
| HALO | New | HALOZYME THERAPEUTICS INCcall | $1,551,000 | – | 160,700 | +100.0% | 0.78% | – |
| ARRY | New | ARRAY BIOPHARMA INCcall | $1,080,000 | – | 228,400 | +100.0% | 0.55% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.